SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …

Carbohydrates are fundamental molecules involved in nearly all aspects of lives, such as
being involved in formating the genetic and energy materials, supporting the structure of …

Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …

Sodium-Glucose Cotransporter 2 inhibitors (SGLT2i), or gliflozins, are a group of antidiabetic
drugs that have shown improvement in renal and cardiovascular outcomes in patients with …

Diabetes, a silent killer, is one of the most widely prevalent conditions of the present time.
According to the 2017 International Diabetes Federation (IDF) statistics, the global …

Kidney size and glomerular filtration rate (GFR) often increase with the onset of diabetes,
and elevated GFR is a risk factor for the development of diabetic kidney disease …

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin,
and canagliflozin, are now widely approved antihyperglycemic therapies. Because of their …

The kidney has a pivotal role in maintaining glucose homeostasis by using glucose as a
metabolic fuel, by producing glucose through gluconeogenesis, and by reabsorbing all …

The kidney is arguably the most important target of microvascular damage in diabetes. A
substantial proportion of individuals with diabetes will develop kidney disease owing to their …

Diabetes mellitus is a complex metabolic disorder associated with an increased risk of
microvascular and macrovascular disease; its main clinical characteristic is hyperglycaemia …